CD80 and cancer: The authors propose that combining antibodies targeting PD-L1 (to disrupt both trans PD-1/PD-L1 and cis PD-L1/CD80 interactions) with anti-CTLA-4 antibodies might further enhance T-cell reinvigoration in cancer patients.